Aurinia Pharmaceuticals : Modern Slavery Report

DocuSign Envelope ID: 6596548B-DE3E-4735-8F00-FABEFF931AEC

Forced Labour and Child Labour Report 2023

Aurinia Pharmaceuticals Inc.

This Forced Labour and Child Labour Report (the "Report") addresses the period from January 1, 2023 to December 31, 2023 and has been prepared in compliance with the Fighting Against Forced Labour and Child Labour in Supply Chains Act (Canada) (the "Act"). This Report is made on behalf of Aurinia Pharmaceuticals Inc. ("Aurinia", "we", "us" or "our").

1. Introduction

The Fighting Against Forced Labour and Child Labour in Supply Chains Act (the "Act") requires that businesses report on the actions they have taken during the fiscal year to prevent and reduce the risk of forced labour or child labour within their operations and supply chain. This Report sets out the steps we have taken during Fiscal Year 2023 to prevent and reduce the risk that forced labour or child labour is used at any step in the production of goods in Canada or elsewhere by Aurinia or of goods imported into Canada by Aurinia.

2. Our Structure, Activities and Supply Chain

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration ("FDA") approved oral therapy for the treatment of adult patients with active lupus nephritis ("LN") and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") as a collaboration partner for development and commercialization of LUPKYNIS in the European Union ("EU"), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the "Otsuka Territories").

On September 15, 2022, the European Commission ("EC") granted marketing authorization of LUPKYNIS to Otsuka. The centralized marketing authorization is valid in all EU member sates as well as in Iceland, Liechtenstein, Norway, and Northern Ireland.

Aurinia's head and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.

Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company's common shares are traded on the Nasdaq Global Market ("Nasdaq") under the symbol AUPH.

Aurinia's supply chain includes businesses in connection with the manufacturing of voclosporin. Voclosporin is manufactured by Lonza Ltd. ("Lonza"), our sole supplier for drug substances. Voclosporin is manufactured within Lonza's small molecule facility in Visp, Switzerland. Catalent Pharma Solutions is currently the sole supplier for the preparation of our voclosporin 7.9 mg

DocuSign Envelope ID: 6596548B-DE3E-4735-8F00-FABEFF931AEC

capsules and is located in Saint Petersburgh, Florida. We use Packaging Coordinators Inc. ("PCI") as our sole supplier for the blistering and packaging of LUPKYNIS commercial cartons for sale in the United States and for the blistering of semi-finished products, at their facilities in Philadelphia, Pennsylvania. The company uses a third-party logistics provider Cardinal Health to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf.

3. Our Policies and Due Diligence

Policies

Through our organizational and governance policies we communicate our values and expectations, for ourselves, our suppliers, and our selling partners. We are committed to consistently evolving and improving our approach. We strongly discourage child, forced or bonded labour at all points in our processes, from sourcing the raw materials to manufacture LUPKYNIS to the creation of the final product.

Code of Ethics and Conduct

We are committed to conducting our business in a lawful and ethical manner. Aurinia is dedicated to maintaining our reputation for integrity and good corporate citizenship and expects all employees to abide by basic principles of ethical and lawful business conduct. Our Code of Ethics and Conduct (the "Code") is the foundation of our corporate policies and sets out guiding principles on professional conduct and establishes that in performing their job duties, Aurinia employees should always act lawfully, ethically and in the best interests of Aurinia.

Whistleblower Policy

In accordance with our Whistleblower Policy, it is the responsibility of all of Aurinia's directors, officers, and employees to comply with the Code and to report actual or suspected misconduct, illegal activities or fraud. Aurinia provides several methods of reporting misconduct including to an employee's manager, Aurinia's Chief Compliance Officer, our Legal Department or an independent and confidential hotline managed by a third-party and open 24 hours a day, 7 days a week.

Due Diligence

We acknowledge that employees working in our offices and in the facilities of the entities in our supply chain are at potential risk of being the subjects of forced or child labour. We expect all third parties (Aurinia's suppliers described in section 2 of this Report) with which we work to adhere to business principles and values similar to our own and to comply with all applicable laws and regulations. Although Aurinia does not currently have a due diligence process in relation to forced and child labour specifically, we make reasonable efforts to monitor the performance of our suppliers to prevent any activities that could have a negative impact with respect to forced or child labour. The company and the FDA has conducted various audits at our suppliers that revealed no instances of forced labour or child labour. We are working to review our due diligence processes

DocuSign Envelope ID: 6596548B-DE3E-4735-8F00-FABEFF931AEC

and explore the possibility of implementing further due diligence steps in relation to forced and child labour.

4. Assessing Our Risk

Due to the nature of our business, we and our suppliers are heavily regulated, and subject to significant regulatory oversight. We follow all applicable regulations and laws according to the industry in which we work, and the jurisdictions in which we operate (including applicable child and forced labour laws). This extends to our corporate risk management approach. Our exposure to the risk of forced labour and/or child labour increases when we engage with third party suppliers, which is mitigated by the heavy regulations and oversight the pharmaceutical industry places on our suppliers and through our own policies, procedures and due diligence.

We therefore assess the risk of exposure to forced and child labour in our business and supply chain as low.

Aurinia makes reasonable efforts to ensure our suppliers follow applicable laws and regulations.

Since the reporting period ended, we are in the process of updating language in our master service agreements, request for proposals and vendor contracts to actively refer to provisions relating to activities our suppliers must undertake or represent regarding forced and child labour prevention and reduction.

5. Our Commitments

Our Code and Whistleblower Policy requires all directors, officers, and employees to report actual or possible misconduct. We also undertake diligence efforts (as further described in this Report) to ensure that the risk of forced labour and child labour is mitigated in our business. Our hiring practices ensures that we hire age-appropriate labour.

While no reports or complaints regarding forced labour or child labour regarding our or, to our knowledge, our suppliers have been received at the time of filing this Report, should such circumstances arise, we are dedicated to upholding our commitments to combat these issues while actively working to mitigate any resulting adverse impacts, including financial, on the Company and our operations. We did not identify any instances of forced or child labour in our operations or supply chain during the reporting period. Accordingly, we did not implement any measures to remediate forced or child labour or to remediate the loss of income to the most vulnerable families arising from such measures.

At least annually, Aurinia personnel at all levels are required to complete mandatory general training which includes any new upcoming regulations and procedures. Although Aurinia's employee training does not currently include dedicated training on forced and child labour explicitly, every new employee of Aurinia must complete mandatory training on our values and

DocuSign Envelope ID: 6596548B-DE3E-4735-8F00-FABEFF931AEC

policies, including our Code, and is informed of how to report wrongdoing under our Whistleblower Policy.

6. Our Progress and Effectiveness

As part of our governance processes, we use Veeva vault to monitor employees' compliance with our policies on an ongoing basis. We also review any concerns raised through our Whistleblower Policy and other informal mechanisms of employee feedback. To date no significant concerns or complaints related to forced and child labour have been identified.

As we strive to be more accountable to our customers and communities, we will use reasonable efforts to disclose how we are performing, where we are improving and where we need to improve. Disclosure of our progress is important to build trust with our stakeholders and show that we are dedicated to respecting our engagements. Recognizing the inherent complexity in assessing the effectiveness of our actions to prevent and reduce the risk of forced or child labour in our supply chain, we acknowledge the importance of such evaluations in mitigating risks. While we have yet to establish formal policies and procedures for evaluating the effectiveness of the varied measures implemented to mitigate the risk of forced labour and child labour within our operations and supply chains, Aurinia aims to keep our policies and procedures under review and to explore additional steps for assessing their effectiveness.

Approval & Signature

This Report was approved by Aurinia's board of directors on May 29, 2024 and has been submitted to the Minister of Public Safety and Emergency Preparedness in Canada. This Report is also available on our company website at www.https://www.auriniapharma.com/and on our profile on SEDAR+ at www.sedarplus.ca.

In accordance with the requirements of the Act, and in particular section 11 thereof, I attest that I have reviewed the information contained in this Report for the entity listed above. Based on my knowledge, and having exercised reasonable diligence, I attest that the information in this Report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed above.

Signed and approved this 29 day of May, 2024.

Name: Daniel Billen

Title: Chair of Comp Committee

I have the authority to bind Aurinia.